Search

Your search keyword '"MASCAGNI, F."' showing total 176 results
Start Over Author "MASCAGNI, F."
176 results on '"MASCAGNI, F."'

3. A whole genome analysis of long-terminal-repeat retrotransposon transcription in leaves of Populus trichocarpa L. subjected to different stresses

Author

Vangelisti, A., Usai, G., Mascagni, F., Natali, L., Giordani, T., and Cavallini, A.

Subjects
retrotransposon expression, Illumina cDNA libraries, Populus trichocarpa, lcsh:Cytology, LTR-retrotransposons, Retrotransposon abundance, Retrotransposon expression, genetic processes, fungi, information science, food and beverages, retrotransposon abundance, lcsh:Biology (General), health occupations, lcsh:QH573-671, lcsh:QH301-705.5
Abstract

Long terminal repeat retrotransposons have a main role in shaping the structure of plant genomes. We used available genomic resources to study as several factors affect the expression of long terminal repeat retrotransposons in Populus trichocarpa. Such factors included redundancy of a retrotransposon in the genome, chromosomal localization, “genotype” of the retrotransposon, and changes in the environment. Overall, we identified and annotated 828 full-length retrotransposons, and analyzed their abundance in the genome. Then, we measured their expression in leaves of plants subjected to several stresses (drought, cold, heat, and salt) as well as in control plants. Our analyses showed that the expression of retrotransposons was generally low, especially that of abundant elements. The transcription of an element was found to be only slightly dependent on its chromosomal localization, rather it depended on the superfamily and the lineage to which the retrotransposon belonged. Finally, some retrotransposons were specifically activated by different environmental stresses., Caryologia. International Journal of Cytology, Cytosystematics and Cytogenetics, V. 72 N. 2 (2019)

Published
2020
Full Text
View/download PDF

46. {beta}-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure.

Author

Ambrosio G, Flather MD, Böhm M, Cohen-Solal A, Murrone A, Mascagni F, Spinucci G, Conti MG, van Veldhuisen DJ, Tavazzi L, and Coats AJ

Abstract

Objectives This subanalysis of the Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalisation in Seniors with Heart Failure (SENIORS) investigates whether treatment with nebivolol, a [beta]-blocker with nitric oxide-releasing properties, can provide additional benefits besides its effects on heart failure (HF), by reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. Design A double-blind, randomised, placebo-controlled, multicentre trial of nebivolol in 2128 elderly patients. Patients and interventions For this analysis, data were extracted for 2128 elderly (>=70years) HF patients in whom coronary artery disease (CAD) was the underlying aetiology (68.2%; 717 placebo-treated patients and 735 assigned to nebivolol). Main outcome measures The main endpoint was the composite of cardiac ischaemic events at 2year follow-up: death/hospitalisation for myocardial infarction, unstable angina or sudden death, as originally identified in the case report form. Results At follow-up, nebivolol treatment was associated with a one-third reduction in the risk of ischaemic events, the composite endpoint occurring in 15.9% of placebo and 10.7% of nebivolol-treated patients (HR 0.68; 95% CI 0.51 to 0.90; p=0.008). This effect was independent of age, gender and ejection fraction. No difference in this composite endpoint was observed in the subgroup of patients of non-ischaemic aetiology. Conclusions Nebivolol was effective in reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. The prevention of ischaemic events can be an additional beneficial effect of [beta]-blockade in HF patients with underlying CAD. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results